WallStreetZenWallStreetZen

NASDAQ: BEAT
Heartbeam Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for BEAT

Based on 1 analyst offering 12 month price targets for Heartbeam Inc.
Min Forecast
$8.00+282.78%
Avg Forecast
$8.00+282.78%
Max Forecast
$8.00+282.78%

Should I buy or sell BEAT stock?

Based on 1 analyst offering ratings for Heartbeam Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BEAT stock forecasts and price targets.

BEAT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-25

1 of 1

Forecast return on equity

Is BEAT forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.66%

Forecast return on assets

Is BEAT forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

BEAT revenue forecast

What is BEAT's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$16.7M
Avg 2 year Forecast
$49.4M
Avg 3 year Forecast
$88.9M

BEAT vs Health Information Service Stocks

TickerPricePrice TargetUp/downsideConsensus
BEAT$2.09$8.00+282.78%Buy
EUDA$1.69N/AN/A
RNLX$0.79N/AN/A
NUTX$0.66$15.00+2,190.08%Strong Buy
FORA$2.52$5.00+98.41%Strong Buy
View Top Health Information Service Stocks

Heartbeam Stock Forecast FAQ

Is Heartbeam Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BEAT) stock is to Buy BEAT stock.

Out of 1 analyst, 0 (0%) are recommending BEAT as a Strong Buy, 1 (100%) are recommending BEAT as a Buy, 0 (0%) are recommending BEAT as a Hold, 0 (0%) are recommending BEAT as a Sell, and 0 (0%) are recommending BEAT as a Strong Sell.

If you're new to stock investing, here's how to buy Heartbeam stock.

What is BEAT's revenue growth forecast for 2024-2026?

(NASDAQ: BEAT) Heartbeam's forecast annual revenue growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 13.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Heartbeam's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast BEAT's revenue for 2024 to be $439,694,834, with the lowest BEAT revenue forecast at $439,694,834, and the highest BEAT revenue forecast at $439,694,834. On average, 1 Wall Street analysts forecast BEAT's revenue for 2025 to be $1,299,864,310, with the lowest BEAT revenue forecast at $1,299,864,310, and the highest BEAT revenue forecast at $1,299,864,310.

In 2026, BEAT is forecast to generate $2,340,387,654 in revenue, with the lowest revenue forecast at $2,340,387,654 and the highest revenue forecast at $2,340,387,654.

What is BEAT's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: BEAT) forecast ROA is N/A, which is lower than the forecast US Health Information Services industry average of N/A.

What is BEAT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BEAT price target, the average BEAT price target is $8.00, with the highest BEAT stock price forecast at $8.00 and the lowest BEAT stock price forecast at $8.00.

The Wall Street analyst predicted that Heartbeam's share price could reach $8.00 by Mar 25, 2025. The average Heartbeam stock price prediction forecasts a potential upside of 282.78% from the current BEAT share price of $2.09.

What is BEAT's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: BEAT) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.